New Generation of Antibody-Drug Conjugates (ADCs) Shows Unprecedented Promise in Early-Stage Disease

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer

Source